INKmune is an immuno-oncology drug, part of the fastest growing sector of anti-cancer therapies. The global market for cancer drugs hit $100 billion in annual sales in 2015 and could reach nearly $150 billion by 2018 according to IMS Health. Modern cancer therapies should be safe, effective, easy-to-use and use a precision medicine strategy that matches the patient’s disease with the treatment. Inmune Bio is using biomarkers to identify patients whose immune system needs help in combating their cancer. This precision medicine approach should improve the efficiency of INKmune therapy and improve cancer care. INKmune therapy is delivered as a simple, once-a-month intravenous infusion. This simplicity will allow for use in cancer treatment centers everywhere to treat a wide variety of tumor types.

Market Opportunity:  INKmune is a broadly applicable immuno-oncology treatment for a variety of hematologic malignancies including AML (acute myelogenous leukemia), MM (multiple myeloma), lymphoma, and solid tumors including breast, ovarian, lung, renal, pancreas and prostate cancer. INmune’s development strategy is to focus development on orphan drug indications in cancers with few effective treatment options. The initial clinical development programs will focus on AML and ovarian cancer. Market expansion into other types of cancers will occur in the future.

Market Incidence Penetration Value (x$1000)
AML 20,830 60% $749,880
Ovary 21,290 50%

$638,700

MM 26,850 25% 402,750
Pancreas 48,960 60% 1,762,560

Acute Myeloid Leukemia (AML) is a fast growing form of blood system cancer that, if left untreated, is universally fatal. AML begins in bone marrow where blood cells are produced.  As the AML grows, the cancer crowds out the patient’s normal cells in the bone marrow until there are few normal cells in the patient’s blood stream.  , Patients often present their physician with bleeding or infection as the first symptoms.  Fortunately, almost all patients can be put into remission with chemotherapy.  Unfortunately, a majority  will relapse within the first two years and eventually die of their disease..

AML is one of the most common types of leukemia in adults, yet continues to have the lowest survival rate of all leukemias. The estimated five-year survival rate of patients diagnosed with AML between 1999 and 2006 was approximately 24 percent in the United States.  Athough adult AML can occur at any age, survival worsens as age increases.  The median age of patients diagnosed with adult AML is 67 years.  More than half of adult patients developing AML are older than 65 years old.  AML in elderly pateints is a catastrophic disease for at least three reasons:  i)  they most commonly get an aggressive subtype that is more difficult to treat and has a worse prognosis; ii) because of other medical conditions, their treatment options are limited; finally, iii) when they are put into remission, their remission tends to be shorter.  These factors, combined with the demographic reality of longer life span where the number of elderly patients expanding much faster than the general population means that the number of adults getting AML will be increasing, the AML they get is worst and the need for effective therapies becomes more acute.  

Ovarian Cancer: Ovarian cancer is a disease in which, depending on the type and stage of the disease, malignant (cancerous) cells are found inside, near, or on the outer layer of the ovaries. In most cases, the cancer has metastasize beyond the ovary, usually in the abdominal cavity.  The American Cancer Society estimates that there will be over 22,280 new cases of ovarian cancer diagnosed this year and that more than 14,240 women will die from ovarian cancer this year. When a woman is diagnosed and treated in the earliest stages of disease, the five-year survival rate is over 90 percent. Unfortunately, due to ovarian cancer's non-specific symptoms and lack of early detection tests, only one fifith of all cases are found early when treatment is most effective. For the unfortunate majority with more advance disease , , less than a third of the women will survive for five years.   Nearly three fourths of patients diagnosed with ovarian cancer are older than 55, most often between the ages fo 55 and 65.  To put this in perspective, the  average life expectany of a 60 year old woman in 86 years old.  If that woman has advanced ovarian cancer, the chance of her living 5 years is less than 30%.  Ovarian cancer is an awful disease that dramatically shortens the life of women with advanced disease.  

Have a Question?
858 964 3720
Email Us
dmoss@inmunebio.com
Opening Hours
M - F 8am to 5pm PST